(NASDAQ: LGND) Ligand Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 62.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.6%.
Ligand Pharmaceuticals's revenue in 2024 is N/A.On average, 2 Wall Street analysts forecast LGND's revenue for 2024 to be $2,465,461,215, with the lowest LGND revenue forecast at $2,429,165,376, and the highest LGND revenue forecast at $2,501,757,053. On average, 2 Wall Street analysts forecast LGND's revenue for 2025 to be $2,757,686,977, with the lowest LGND revenue forecast at $2,723,073,141, and the highest LGND revenue forecast at $2,792,300,813.
In 2026, LGND is forecast to generate $3,257,595,755 in revenue, with the lowest revenue forecast at $3,257,595,755 and the highest revenue forecast at $3,257,595,755.